Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors
Immune checkpoint inhibitors (ICIs) can block distinct receptors on T cells or tumor cells thus preventing T cell inactivation and tumor immune escape. While the clinical response to treatment with ICIs in cancer patients is impressive, this therapy is often associated with a number of immune-relate...
Main Authors: | Johanna Reul, Janina Frisch, Christine E. Engeland, Frederic B. Thalheimer, Jessica Hartmann, Guy Ungerechts, Christian J. Buchholz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00052/full |
Similar Items
-
AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma
by: M.I. Strecker, et al.
Published: (2022-12-01) -
Evaluation of AAV-DJ vector for retinal gene therapy
by: Yusaku Katada, et al.
Published: (2019-01-01) -
Accurate Quantification of AAV Vector Genomes by Quantitative PCR
by: Cristina Martinez-Fernandez de la Camara, et al.
Published: (2021-04-01) -
Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency
by: Mathieu Mével, et al.
Published: (2024-03-01) -
Impact of mechanical stimulation on the chondrogenic processes in human bone marrow aspirates modified to overexpress sox9 via rAAV vectors
by: Jagadeesh K. Venkatesan, et al.
Published: (2017-06-01)